Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Endothelial Barriers and Vascular Function: Study Summary

Previous related pageVitamin D, Endothelial Barriers and Vascular Function: Full StudyNext related pageVitamin D, Endothelial Barriers and Vascular Function: Full Study
Study at a glance

How might vitamin D-related treatments affect blood-vessel linings?

The endothelium is the cell layer lining blood vessels. It helps control what passes through the vessel wall and how vessels respond to signals. This page compares laboratory tests of barrier strength with human trials of vessel responses. A tighter barrier and a vessel that widens more easily are different findings.

Did an active vitamin D-like drug reduce leakage in laboratory tests?

Paricalcitol, a drug similar to active vitamin D, reduced leakage through the lining of the main artery in rats with experimentally caused kidney disease. A vitamin D-deficient diet did not significantly alter leakage in this experiment. In human cells grown in the laboratory, the higher tested drug concentration strengthened the barrier and reduced disruption during a laboratory challenge. These experiments used cells from three donors. They did not show improved wound healing or fewer heart attacks in people.

Did vitamin D2 improve blood-vessel responses in people?

A six-month trial assigned 38 adults with kidney disease and low vitamin D to vitamin D2 or placebo. One test of small blood vessels in the skin improved, but other vessel tests did not show matching benefits. Recruitment was below the planned number, and follow-up was incomplete. A second trial assigned 93 overweight or obese adults without high blood pressure or established heart disease. After eight weeks, vitamin D2 raised blood levels but did not significantly improve widening of the upper-arm artery compared with placebo.

Do these findings establish a vitamin D treatment for heart and circulation problems?

The studies used different treatments, people and measurements. A positive cell result does not establish a treatment benefit, and a negative trial does not rule out every possible effect in other settings. None of these experiments established fewer heart attacks or strokes. They do not define a supplement dose, a vitamin D blood target or a proven treatment for heart and circulation problems.

Read the full article below ↓

Vitamin D-related signalling can affect the endothelial cells lining blood vessels, but barrier strength and vessel relaxation are different outcomes. A laboratory study found that an active vitamin D analogue stabilised endothelial barriers. Human vitamin D2 trials produced different results for different vascular tests. For the detailed methods and appraisal, read Vitamin D, Endothelial Barriers and Vascular Function: Full Study.

What the barrier study tested

Vila Cuenca and colleagues studied paricalcitol, a synthetic active vitamin D analogue, in rats with surgically induced kidney disease and in cultured human umbilical-vein endothelial cells. This was not a trial of ordinary vitamin D3 supplements in patients. The endothelial function overview explains why both the lining’s barrier and its signalling functions matter.

The rat experiment compared kidney disease, vitamin D-deficient diet and treatment across eight groups of six to eight animals. Four of the 32 rats undergoing kidney surgery died during the operation. Healthy controls did not undergo sham surgery. Treatment lasted seven weeks, and some endpoint analyses contained fewer animals than the initial groups.

What changed in the laboratory

Kidney disease increased passage of Evans Blue dye into the aortic wall. Paricalcitol reduced this leakage and was associated with fewer gaps in the endothelial lining. The deficient diet did not significantly alter the leakage outcome in this model. That finding does not support a simple explanation in which low dietary vitamin D alone caused the barrier defect.

In cultured human cells, the higher paricalcitol concentration increased electrical resistance across the cell layer by about 8.4%, consistent with a tighter barrier. Microscopy showed stronger cell-junction staining. After a thrombin challenge, resistance fell by about 35% with the higher exposure versus 45% in controls. These are percentage drops from baseline, not percentages of clinical benefit.

Paricalcitol also improved recovery after electrical injury to the cultured layer. The experiments used cells from three healthy donors, and did not show better wound healing or fewer cardiovascular events in patients. Measurements did not establish a significant restoration of α-Klotho, a kidney-associated protein, but that does not exclude every contribution from this pathway.

A positive, but small, human trial

Dreyer and colleagues randomised 38 adults with non-diabetic chronic kidney disease and vitamin D deficiency to vitamin D2 or placebo for six months. The treated group had a better forearm skin response to acetylcholine, an endothelial-dependent stimulus. The trial measured local laser Doppler flux, not blood flow through the heart.

The response to sodium nitroprusside, an endothelium-independent vasodilator, did not significantly improve. Aortic stiffness and sublingual microcirculatory tests did not show matching benefits. The protocol had planned 80 participants and several vascular endpoints, and not all participants provided six-month data. The positive finding therefore needs confirmation in a larger trial.

A second human trial found no clear benefit

Borgi and colleagues randomised 93 overweight or obese adults with low vitamin D status but without hypertension or established cardiovascular disease; 84 completed follow-up. Eight weeks of vitamin D2 raised vitamin D concentrations without significantly improving brachial-artery endothelial-dependent vasodilation versus placebo. The journal later corrected Figure 3.

This null finding does not prove that vitamin D has no vascular effects under any circumstances. It shows that the tested replacement regimen did not establish benefit for this outcome in this selected population. The study differed from the kidney-disease trial in participants, duration and the part of the circulation measured.

What readers can conclude

The studies address different steps within heart and circulatory physiology. Better barrier resistance in cells, a stronger skin microvascular response and improved large-artery relaxation are not the same result. None of these experiments established fewer heart attacks or strokes.

The distinction between vitamin D status and vitamin D effect prevents overinterpretation: a blood concentration is not a direct measure of every tissue response. These findings support further investigation of endothelial mechanisms and carefully specified human outcomes. They do not define a supplement dose, a blood target or a proven cardiovascular treatment.

Scientific sources

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018;7(17):e008776. DOI: 10.1161/JAHA.118.008776. PMID: 30371149. Principal barrier experiment, including supplementary kidney-function and α-Klotho results.

Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM. Ergocalciferol and Microcirculatory Function in Chronic Kidney Disease and Concomitant Vitamin D Deficiency: An Exploratory, Double Blind, Randomised Controlled Trial. PLoS ONE. 2014;9(7):e99461. DOI: 10.1371/journal.pone.0099461. PMID: 25006678. Human microcirculatory trial; its supplementary methods and study protocol inform the appraisal.

Borgi L, McMullan C, Wohlhueter A, Curhan GC, Fisher ND, Forman JP. Effect of Vitamin D on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Hypertension. 2017;30(2):124-129. DOI: 10.1093/ajh/hpw135. PMID: 28077419. Human supplementation comparison.

Correction to Borgi and colleagues: Erratum. American Journal of Hypertension. 2017;30(7):731. DOI: 10.1093/ajh/hpx030. PMID: 28472334. Replaces Figure 3; the numerical comparison discussed here is reported in the article text.

Related reading

Original sources

Source

Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability

Published in Journal of the American Heart Association (2018).

Publication details

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018;7(17):e008776. DOI: 10.1161/JAHA.118.008776. PMID: 30371149. Principal barrier experiment, including supplementary kidney-function and α-Klotho results.

Read more →
Source

Erratum

Published in American Journal of Hypertension (2017).

Publication details

Correction to Borgi and colleagues: Erratum. American Journal of Hypertension. 2017;30(7):731. DOI: 10.1093/ajh/hpx030. PMID: 28472334. Replaces Figure 3; the numerical comparison discussed here is reported in the article text.

Read more →